Evidence map›Paper›PMID 36640142›Full record

ArticleThe oncologist2023

HiJAKing Immunotherapy-Resistant Melanoma for a Cure.

Lewis Zhichang Shi, Hongxing Shen, Oluwagbemiga A Ojo, James A Bonner

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lewis Zhichang ShiDepartment of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0002-5351-8730
Hongxing ShenDepartment of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
Oluwagbemiga A OjoDepartment of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
James A BonnerDepartment of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.ORCID 0000-0002-8413-3788

Funding

T cell-intrinsic metabolic control of radiotherapyR01CA279849 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Lewis Z. Shi · 2024 to 2026
$1.2M
Overcoming Tumor-Intrinsic Therapeutic Resistance to ImmunotherapiesR21CA259721 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2022 to 2023
$378k
Targeting metabolic checkpoints in the tumor microenvironment to boost efficacy of anti-CTLA-4R21CA230475 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHI, LEWIS ZHICHANG · 2019 to 2020
$355k
NCI NIH HHS R01 CA279849NCI NIH HHS R21 CA230475NCI NIH HHS R21 CA259721NIH HHS 1R21CA230475-01A1
6 · The paper itself

Abstract

Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.

Indexed as

Drug Resistance, NeoplasmImmune Checkpoint InhibitorsImmunotherapyMelanomaHumansImmune Checkpoint Inhibitorsimmune checkpoint blockersJAK inhibition (JAKi)melanoma

Identifiers

PMID36640142
PMCPMC10020808

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read5
identifiers read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.